Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Dimethyl Sulfoxide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL28526972 | 0.88 | CA5A (0.50) | — | |
| Sulfuric Acid SCHEMBL28550855 | 0.85 | CA5A (0.46) | — | |
| Sulfuric Acid SCHEMBL28210526 | 0.85 | CA5A (0.46) | — | |
| Sulfuric Acid SCHEMBL28210525 | 0.85 | CA5A (0.46) | — | |
| Dimethyl Sulfone SCHEMBL918316 | 0.84 | — | — | |
| Dimethyl Sulfoxide SCHEMBL14935714 | 0.79 | CA2 (0.37) | — | |
| SCHEMBL25599 | 0.78 | CA2 (0.58) | — | |
| SCHEMBL8596055 | 0.78 | CA2 (0.58) | — | |
| SCHEMBL15109974 | 0.78 | — | — | |
| SCHEMBL105 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111689897-B | Preparation method of high-purity lenvatinib mesylate crystal form C | 齐鲁制药有限公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-113999173-A | Preparation method of high-purity crystal | 药源药物化学（上海）有限公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-111689897-A | Preparation method of high-purity Levatinib mesylate crystal form C | 齐鲁制药有限公司 | 2020-09-22 | — | — | CN | disclosed |